Advertisement

A 35-Year-Old Woman with Whole Body Pain: Fibromyalgia

  • Lynn R. KohanEmail author
  • Xiaoying Zhu
Chapter
  • 43 Downloads

Abstract

Fibromyalgia is a disease that can significantly impact the quality of life of numerous patients. Patients present with widespread pain in addition to associated symptoms such as sleep disturbances, cognitive dysfunction, depression, anxiety, and fatigue. The disease is more prevalent among women. While there is no cure for fibromyalgia, symptoms can be decreased with the appropriate treatment plan. Treatment involves a stepwise approach including patient education, medications, and physical and psychological therapies. Patients who adhere to their treatment plans have the best chance of successful recovery.

Keywords

Fibromyalgia Chronic widespread pain syndrome Whole body pain Fibromyalgia pain treatment Fibrositis syndrome American College of Rheumatology criteria for fibromyalgia 

References

  1. 1.
    Smythe HA, Moldofsky H. Two contributions to understanding of the “fibrositis” syndrome. Bull Rheum Dis. 1977–1978;28(1):928–31.PubMedGoogle Scholar
  2. 2.
    Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160–72.PubMedGoogle Scholar
  3. 3.
    Fitzcharles MA, Boulos P. Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals. Rheumatology (Oxford). 2003;42(2):263–7.Google Scholar
  4. 4.
    Bennett RM. Clinical manifestations and diagnosis of fibromyalgia. Rheum Dis Clin N Am. 2009;35(2):215–32.Google Scholar
  5. 5.
    Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcomemeasures, and treatment. J Rheumatol Suppl 2005;75:6–21. Review. Erratum in: J Rheumatol Suppl. 2005;32(10):2063.Google Scholar
  6. 6.
    Wolfe F, Clauw D, Fitzcharles MA, Goldenberg D, Hauser W, Katz R, Russel A, Russel I, Walitt B. 2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319–29.PubMedGoogle Scholar
  7. 7.
    Sarzi-Puttini P, Atzeni F, Mease PJ. Chronic widespread pain: from the peripheral to central evolution. Best Pract Res Clin Rheumatol. 2011;25(2):133–9.PubMedGoogle Scholar
  8. 8.
    Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology to therapy. Nat Rev Rheumatol. 2011;7(9):518.PubMedGoogle Scholar
  9. 9.
    Goldenberg DL. Do infections trigger fibromyalgia? Arthritis Rheum. 1993;36:1489.PubMedGoogle Scholar
  10. 10.
    Petzke F, Clauw DJ, Ambrose K, Khine A, Gracely RH. Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. Pain. 2003;105(3):403–13.PubMedGoogle Scholar
  11. 11.
    Geisser ME, Glass JM, Rajcevska LD, Clauw DJ, Williams DA, Kileny PR, et al. A psychophysical study of auditory and pressure sensitivity in patients with fibromyalgia and healthy controls. J Pain. 2008;9(5):417–22.PubMedGoogle Scholar
  12. 12.
    Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented central pain processing in fibromyalgia. Arthritiis Rheum. 2002;46:1333–43.Google Scholar
  13. 13.
    Giesecke T, Gracely R, Grant MA, Nachemson A, Petzke F, Williams D, Clauw D. Evidence of augmented central pain processing in idiopathic low back pain. Arthritis Rheum. 2004;50:613–23.PubMedGoogle Scholar
  14. 14.
    Cook DB, Lange G, Ciccone DS, Liu WC, Steffener J, Natelson BH. Functinal imaging of pain in patients with primary fibromyalgia. J Rheumatol. 2004;31:364–78.PubMedGoogle Scholar
  15. 15.
    Jensen KB, Loitoile R, Kosek E, Petzke F, Carville S, Fransson P, Marcus H, Williams SCR, Choy E, Mainguy Y, et al. Patients with fibromyalgia display less functional connectivity in the brain’s pain inhibitory network. Mol Pain. 2012;8:32.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Harte SE, Ichesco E, Hampson JP, Peltier SJ, Schmidt-Wilcke T, Clauw DJ, Harris RE. Pharmacologic attenuation of cross-modal sensory augmentation within the chronic pain insula. Pain. 2016;157:1933.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Schmidt-Wilke T, Diers M. New insights into the pathophysiology and treatment of fibromyalgia. Biomedicine. 2017;5(22):E22.Google Scholar
  18. 18.
    Napadow V, Harris RE. What has functional connectivity and chemical neuroimaging in fibromyalgia taught us about the mechanisms and management of “centralized” pain? Arthritis Res Ther. 2014;16:425.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Gürsoy S, Erdal E, Herken H, Madenci E, Alaşehirli B, Erdal N. Significance of catechol- O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int. 2003;23(3):104–7.PubMedGoogle Scholar
  20. 20.
    Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci. 2007;27(37):10000–6.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311:1547–55.PubMedGoogle Scholar
  22. 22.
    Arnold L, Clauw D, Dunegan J, Turk D. A framework for fibromyalgia management for primary care providers. Mayo Clinic Proc. 2012;87(5):488–96.Google Scholar
  23. 23.
    Arnold LM. Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Res Ther. 2006;8:212.PubMedPubMedCentralGoogle Scholar
  24. 24.
    White KP, Speechley M, Harth M, Ostbye T. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario: the London Fibromyalgia Epidemiology Study. Arthritis Rheum. 1999;42(1):76–83.PubMedGoogle Scholar
  25. 25.
    Blyth FM, March LM, Brnabic AJM, Jorm LR, Williamson M, Cousins MJ. Chronic pain in Australia: a prevalence study. Pain. 2001;89:127–34.PubMedGoogle Scholar
  26. 26.
    Harker, J.; Reid, K.J.; Bekkering, G.E.; Kellen, E.; Malgorzata, M.; Riemsma, R.; Worthy, G.; Misso, K.; Kleijnen, J. Epidemiology of chronic pain in Denmark and Sweden. Pain Res. Treat 2012; Art ID 371248:1–30.Google Scholar
  27. 27.
    Manchikanti L, Singh V, Datta S, Cohen SP, Hirsch J. A comprehensive review of epidemiology, scope, and impact of spinal pain. Pain Physician. 2009;12:E35–70.PubMedGoogle Scholar
  28. 28.
    Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheumatol. 1995;38:19–28.Google Scholar
  29. 29.
    Assumpção A, Cavalcante A, Capela C, Al E. Prevalence of fibromyalgia in a low socioeconomic status population. BMC Musculoskelet Disord. 2009;10:64–70.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Baskila D, Neumann I. Fibromyalgia syndrome (FM) and nonarticular tenderness in relatives of patients with FM. J Rheumatol. 1997;24(5):941–0.Google Scholar
  31. 31.
    Chen J, Mckenzie-Brown AM. The epidemiology and prevalence of fibromyalgia syndrome. In: Lawson E, Wallace M, editors. Fibromyalgia: clinical guidelines and treatments. Switzerland: Springer Publishing; 2015.. Chapter 1.Google Scholar
  32. 32.
    Goldenberg D. Diagnosis and differential diagnosis of fibromyalgia. Am J Med. 2009;122(12):S14–21.PubMedGoogle Scholar
  33. 33.
    Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Winfield JB, Yunus MB. Ther American college of rheumatology preliminary criteria for fibromyalgia and measurement of symptoms severity. Arthritis Care Res. 2010;62(5):600–10.Google Scholar
  34. 34.
    Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76:318–28.PubMedGoogle Scholar
  35. 35.
    Rico-Villademoros F, Slim M, Calandre EP. Amitriptyline for the treatment of fibromyalgia: a comprehensive review. Expert Rev Neurother. 2015;15:1123–50.PubMedGoogle Scholar
  36. 36.
    Kwiatek R. Treatment of fibromyalgia. Aust Prescr. 2017;40:179–83.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;1:CD007115.Google Scholar
  38. 38.
    Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2015;10:CD008244.Google Scholar
  39. 39.
    Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin—Calcium channel α2-Δ [cavα2-Δ] ligands. Pain. 2009;142:13–6.PubMedGoogle Scholar
  40. 40.
    Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP Jr, LaMoreaux LK, Martin SA, Sharma U. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–73.PubMedGoogle Scholar
  41. 41.
    Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;Google Scholar
  42. 42.
    Üçeyler N, Sommer C, Walitt B, Häuser W. Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev. 2013;10:CD010782.Google Scholar
  43. 43.
    Cooper TE, Derry S, Wiffen PJ, Moore RA. Gabapentin for fibromyalgia in adults. Cochrane Database Syst Rev. 2017;(1):CD012188.Google Scholar
  44. 44.
    Walitt B, Urrútia G, Nishishinya MB, Cantrell SE, Häuser W. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. Cochrane Database Syst Rev. 2015;6Google Scholar
  45. 45.
    Littlejohn GO, Guymer EK, Ngian GS. Is there a role for opioids in the treatment of fibromyalgia? Pain Manag. 2016;6:347–55.PubMedGoogle Scholar
  46. 46.
    Kia S, Choy E. Update on treatment guidelines in fibromyalgia syndrome with focus on pharmacology. Biomedicine. 2017;5(2):20.Google Scholar
  47. 47.
    Derry S, Wiffen PJ, Häuser W, Mücke M, Tölle TR, Bell RF, Moore RA. Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults. Cochrane Lib. 2016;  https://doi.org/10.1002/14651858.CD012332.
  48. 48.
    Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med. 2003;114:537–45.PubMedGoogle Scholar
  49. 49.
    Bidonde J, Busch A, Schachter C, Overend T, Kim S, et al. Aerobic exercise training for adults with fibromyalgia. Cochrane Database Syst Rev. 2017;(6):CD012700.Google Scholar
  50. 50.
    Sosa-Reina MD, Nunez-Nagy S, Gallego-Izquierdo T, Pecos-Martin D, Monserrat J, Alvarez-Mon M. Effectiveness of therapeutic exercise in fibromyalagia syndrome: a systematic review and meta-analysis of randomized clinical trials. Hindawi Biomed Research International. 2017; Art ID 2356346:1–14.Google Scholar
  51. 51.
    Hauser W, Walitt B, Fitzcharles MA, Sommer C. Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther. 2014;16:201.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Walitt B, Klose P, Fitzcharles MA, et al. Cannabinoids for fibromyalgia. Cochrane Database Syst Rev. 2016;7:CD011694.PubMedGoogle Scholar
  53. 53.
    Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheumatol. 2013;65(2):529–38.Google Scholar
  54. 54.
    Hutchinson MR, Zhang Y, Brown K, Coats BD, Shridhar M, Sholar PW, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008;28:20–9.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Mattioli TA, Miline B, Cahill CM. Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats. Mol Pain. 2010;6:22.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Knijink LM, Dussan-Sarria JA, Rozisky JR, et al. Repetitive transcranial magnetic stimulation for fibromyalgia: a systematic review and meta-analysis. Pain Pract. 2016;16(3):294–304.Google Scholar
  57. 57.
    Woolf C. Central sensitization: implications for the diagnosis and treatment of pain. 2011;152(S3):S2–15.Google Scholar
  58. 58.
    Wolfe F, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62(5):600–10.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of AnesthesiologyUniversity of Virginia Health SystemCharlottesvilleUSA

Personalised recommendations